Peptide Atlas · Protein

Efinopegdutide

Efinopegdutide is a GLP-1 and glucagon receptor co-agonist given by subcutaneous injection once a week.

emerging

provisional
1 citation
0 discussions
0 followers
HM12525A
JNJ-64565111
LAPSGLP/GCG
MK-6024

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 1 citation resolves to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Efinopegdutide reduced liver fat content more than semaglutide over 24 weeks in NAFLD (phase IIa) standing
- resolved
A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
Romero-Gómez M, Lawitz E, Shankar RR, Chaudhri E, Liu J, Lam RLH, Kaufman KD, Engel SS, MK-6024 P001 Study Group
pmid 37355043

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.